[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369102-105":59,"doc-detail-369102-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","enterocyte-like-differentiation-defines-metabolic-gene-signatures-of-cms3-colorectal-cancers-and-provides-therapeutic-vulnerability","Enterocyte-like differentiation deﬁnes metabolic gene signatures of CMS3 colorectal cancers and provides therapeutic vulnerability","","Enterocyte-like differentiation deﬁnes metabolic gene signatures of CMS3 colorectal cancers and provides therapeutic vulnerability. Colorectal cancer is stratified into consensus molecular subtypes (CMS1–4), where CMS3 is metabolic yet its tumorigenic wiring is unclear. Using organoids from 16 genetically engineered mouse models, distinct CMS profiles were modeled and CMS3-like organoids arose with KRAS mutations. Enterocyte-like differentiation in organoids and human cancers drives metabolic signatures, identifying CPS1 and SI as key signature proteins. CPS1 is crucial for de novo pyrimidine synthesis in CMS3 and its inhibition reduces proliferation and stemness selectively, enabling vulnerability targeting.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enterocyte-like-differentiation-defines-metabolic-gene-signatures-of-cms3-colorectal-cancers-and-provides-therapeutic-vulnerability/369102/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enterocyte-like-differentiation-defines-metabolic-gene-signatures-of-cms3-colorectal-cancers-and-provides-therapeutic-vulnerability/369102.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is CMS3 in colorectal cancer and why is it important to study?","Question",{"text":112,"@type":113},"CMS3 is the metabolic molecular subtype of colorectal cancer. Its metabolic characteristics are well defined, but the tumorigenesis wiring and drivers were largely unclear, motivating this study.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were CMS subtypes modeled and compared in the research?",{"text":117,"@type":113},"Organoids derived from 16 genetically engineered mouse models were analyzed after in vitro Cre-recombinase activation. Transcriptional profiling showed that different CMSs (CMS2–4) corresponded to different organoids.",{"name":119,"@type":110,"acceptedAnswer":120},"What drives the metabolic gene signatures in CMS3?",{"text":121,"@type":113},"The metabolic signatures result from enterocyte-like differentiation in both organoids and human cancers, with CPS1 and SI identified as signature proteins.",{"name":123,"@type":110,"acceptedAnswer":124},"Why is CPS1 inhibition considered a therapeutic vulnerability for CMS3?",{"text":125,"@type":113},"CPS1 is crucial for de novo pyrimidine synthesis in CMS3. Inhibition targets proliferation and stemness in CMS3 models, while CMS2 and CMS4 models are not affected.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},369102,1790819140,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":36,"preview_page_count":19,"preview_urls":149},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Article [https://doi.org/10.1038/s41467-024-55574-3](https://doi.org/10.1038/s41467-024-55574-3)  \nEnterocyte-like differentiation deﬁnes metabolic gene signatures of CMS3 colorectal cancers and provides therapeutic vulnerability  \nReceived: 13 April 2023  \n\n| Accepted: 13 December 2024 |\n| --- |\n| |\n| Check for updates |\n\nArezo Torang 1,2,7, Aleksandar B. Kirov1,2,7, Veerle Lammers1,2, Kate Cameron1,2, Valérie M. Wouters 1,2, Rene F. Jackstadt3,4, Tamsin R. M. Lannagan 5,  \nJoan H. de Jong1,2, Jan Koster 1, Owen Sansom 5,6 & Jan Paul Medema1,2   \nColorectal cancer (CRC) is stratiﬁed into four consensus molecular subtypes (CMS1-4). CMS3 represents the metabolic subtype, but its wiring remains largely undeﬁned. To identify the underlying tumorigenesis of CMS3, organoids derived from 16 genetically engineered mouse models are analyzed. Upon in vitro Cre-recombinase activation, transformation is established and transcriptional proﬁling reveals that distinct CMSs (CMS2-4) are modeled with different organoids. CMS3-like, metabolic signature-positive, organoids are induced by KRAS mutations. Interestingly, metabolic signatures are subsequently shown to result from enterocyte-like differentiation both in organoidsand human cancers. Further analysis reveals carbamoyl-phosphate synthase 1 (CPS1) and sucrase-isomaltase (SI) as signature proteins. More importantly, CPS1 is crucial for de novo pyrimidine synthesis in CMS3 and its inhibition targets proliferation and stemness, facilitating enterocyte-like differentiation, while CMS2 and CMS4 models are not affected. Our data point to an enterocyte-like differentiation of CMS3 CRCs and reveal a selective vulnerability of this subtype through CPS1 inhibition.  \nDespite advances in biological understanding of colorectal cancer (CRC) it still remains one ofthe leading causes of cancer-related deaths worldwide1. An important advancement in CRC is the identiﬁcation of biological entities and the use of transcriptional proﬁling to facilitate stratiﬁcation of CRCs into different subtypes2. Four consensus molecular subtypes (CMS1-4) have been deﬁned, where CMS1 is characterized by high microsatellite instability (MSI), hypermutation, BRAF mutations and immune inﬁltration. CMS2 is typically high in somatic copy number alterations (SCNA) and exhibits hyperactivation ofWNT  \nand MYC-pathways. CMS3 has a mixed SCNA phenotype, while it displays the highest incidence ofKRAS mutations and contains high gene expression of a number of metabolic pathways. Finally, CMS4 is SCNA high with increased TGFβ signaling and higher levels of genes involved in epithelial-mesenchymal transition (EMT)2.  \nWhereas CMS subtypes have become a standard in CRC research, the underlying reason for their distinct proﬁles remains largely unknown. To address this, a separate tumour-intrinsic classiﬁer (CRIS) was developed using xenotransplanted cancers proﬁles revealing  \n1Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. 2Oncode Institute, Amsterdam, the Netherlands. 3Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany. 4Heidelberg, Germany Cancer Progression and Metastasis Group, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany. 5Cancer Research UK Scotland Institute, Garscube Estate, Glasgow, UK. 6School of Cancer Sciences, University of Glasgow, Glasgow, UK. 7These authors contributed equally: Arezo Torang, Aleksandar B. Kirov. [e-mail:](e-mail: j.p.medema@amsterdamumc.nl)[ j.p.medema@amsterdamumc.nl](e-mail: j.p.medema@amsterdamumc.nl)  \noverlaps with CMS classiﬁcation although clear distinctions also exist3. Despite these differences, it is evident that the transcriptomic phenotype of all cell types within the entire tumour, as deﬁned by the CMS classiﬁcation, is orchestrated by the tumour cell","cbCaiiMYa7rJ09ge","https://ap.wps.com/l/cbCaiiMYa7rJ09ge","pdf",31109766,16,"English","# Background\n## Colorectal cancer consensus molecular subtypes (CMS1–4)\n# Modeling CMS3 tumorigenesis\n## Organoids from genetically engineered mouse models\n## KRAS-driven CMS3-like metabolic signatures\n# Mechanism and therapeutic vulnerability\n## Enterocyte-like differentiation and signature proteins (CPS1, SI)\n## CPS1-dependent pyrimidine synthesis, proliferation, and stemness","[{\"question\":\"What is CMS3 in colorectal cancer and why is it important to study?\",\"answer\":\"CMS3 is the metabolic molecular subtype of colorectal cancer. Its metabolic characteristics are well defined, but the tumorigenesis wiring and drivers were largely unclear, motivating this study.\"},{\"question\":\"How were CMS subtypes modeled and compared in the research?\",\"answer\":\"Organoids derived from 16 genetically engineered mouse models were analyzed after in vitro Cre-recombinase activation. Transcriptional profiling showed that different CMSs (CMS2–4) corresponded to different organoids.\"},{\"question\":\"What drives the metabolic gene signatures in CMS3?\",\"answer\":\"The metabolic signatures result from enterocyte-like differentiation in both organoids and human cancers, with CPS1 and SI identified as signature proteins.\"},{\"question\":\"Why is CPS1 inhibition considered a therapeutic vulnerability for CMS3?\",\"answer\":\"CPS1 is crucial for de novo pyrimidine synthesis in CMS3. Inhibition targets proliferation and stemness in CMS3 models, while CMS2 and CMS4 models are not affected.\"}]","Enterocyte-like differentiation deﬁnes metabolic gene signatures of CMS3 colorectal cancers and provides therapeutic vulnerability | PDF",1790180757,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b56bd401617a8f431a8656ea3dea092b.webp",983,1305,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21a954fc624f7f410d547204aebf5edb.webp",982,1304,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1fe9eabe1568397107376e2b34477a8.webp",981,1303,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93efe3b45f45386e7c210a6569f0bd98.webp",980,1301]